Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2015, 159(3):437-441 | DOI: 10.5507/bp.2014.020

Glycogen phosphorylase BB levels are associated with haemodynamic parameters in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt insertion

Martina Vasatovaa, Radek Pudilb, Tomas Buchlerc, Iva Karesovaa, Vaclav Safkad, Tomas Fejfard, Petr Hulekd
a Institute of Clinical Biochemistry and Diagnostics, University Hospital in Hradec Kralove, Czech Republic
b 1st Department of Internal Medicine - Cardioangiology, University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University in Prague
c Department of Oncology, 1st Faculty of Medicine, Charles University in Prague and Thomayer University Hospital, Prague
d 2nd Department of Internal Medicine-Gastroenterology, University Hospital in Hradec Kralove and Faculty of Medicine in Hradec Kralove, Charles University in Prague

Background: Transjugular intrahepatic portosystemic shunts (TIPS) have become a widely accepted tool in the treatment of patients with symptomatic portal hypertension. The aim of our study was to assess glycogen phosphorylase BB (GPBB) concentration in relation to echocardiographic and haemodynamic parameters in patients before and after TIPS insertion.

Methods: The study population consisted of 55 patients (38 men and 17 women, age 55.6±8.9 years, range 37-74 years) with liver cirrhosis treated with transjugular portosystemic shunting. GPBB, echocardiographic, and haemodynamic parameters were measured before TIPS insertion and 24 h after the procedure. GPBB concentrations were assessed using the Cardiac Array for Evidence Investigator protein biochip. Correlation between parameters was assessed using the Spearman's coefficient.

Results: Serum post-procedural GPBB concentrations were increased in comparison with baseline (5.58 vs. 2.67 μg/L, P<0.001). GPBB concentration after TIPS significantly correlated with baseline systemic vascular resistence (r=0.330; P=0.017) and cardiac index (r=0.313; P=0.025).

Conclusion: GPBB concentration measurement may be a useful tool for monitoring myocardial ischemia during a TIPS procedure.

Keywords: glycogen phosphorylase BB, cardiac marker, cirrhosis, biochip, portal hypertension, TIPS

Received: October 22, 2013; Accepted: April 7, 2014; Prepublished online: April 29, 2014; Published: September 30, 2015  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vasatova, M., Pudil, R., Buchler, T., Karesova, I., Safka, V., Fejfar, T., & Hulek, P. (2015). Glycogen phosphorylase BB levels are associated with haemodynamic parameters in cirrhotic patients undergoing transjugular intrahepatic portosystemic shunt insertion. Biomedical papers159(3), 437-441. doi: 10.5507/bp.2014.020
Download citation

References

  1. Lee RF, Glenn TK, Lee SS. Cardiac dysfunction in cirrhosis. Best Pract Res Clin Gastroenterol 2007;21:25-40. Go to original source... Go to PubMed...
  2. Huonker M, Schumacher YO, Ochs A, Sorichter S, Keul J, Rössle M. Cardiac function and haemodynamics in alcoholic cirrhosis and effects of the transjugular intrahepatic portosystemic stent shunt. Gut 1999;44:743-8. Go to original source... Go to PubMed...
  3. Schwartz JM, Beymer C, Althaus SJ, Larson AM, Zaman A, Glickerman DJ, Kowdley KV. Cardiopulmonary consequences of transjugular intrahepatic portosystemic shunts: role of increased pulmonary artery pressure. J Clin Gastroenterol 2004;38:590-4. Go to original source... Go to PubMed...
  4. Bernal V, Pascal I, Esquivias P, García-Gil A, Fernández C, Mateo JM, González M, Simón MA. Cardiac hemodynamic profiles and pro-B-type natriuretic peptide in cirrhotic patients undergoing liver transplantaion. Transplant P 2009; 41:985-6. Go to original source... Go to PubMed...
  5. Henriksen JH, Gøtze JP, Fuglsang S, Christensen E, Bendtsen F, Møller S. Increased circulating pro-brain natriuretic peptide (proBNP) and brain natriuretic peptide (BNP) in patients with cirrhosis: relation to cardiovascular dysfunction and severity of disease. Gut 2003;52:1511-7. Go to original source... Go to PubMed...
  6. Pudil R, Praus R, Hůlek P, Safka V, Fejfar T, Vasatova M, Vojacek J. Hemodynamic and echocardiographic changes in patients with liver cirrhosis treated with transjugular intrahepatic portosystemic shunt. Interv Akut Kardiol 2013;12:8-11. Go to original source...
  7. Vasatova M, Pudil R, Safka V, Fejfar T, Buchler T, Hulek P, Palicka V. Elevated cardiac markers are associated with higher mortality in patients after transjugular intrahepatic portosystemic shunt insertion. Ann Clin Biochem 2013;50:122-6. Go to original source... Go to PubMed...
  8. Mair J. Glycogen phosphorylase isoenzyme BB to diagnose ischemic myocardial damage. Clin Chim Acta 1998;272:79-86. Go to original source... Go to PubMed...
  9. Thygesen K, Albert JS, White HD. Universal Definition of Myocardial Infarction. J Am Coll Cardiol 2007;50:2173-95. Go to original source... Go to PubMed...
  10. K. Thygesen, J.S. Alpert, A.S. Jaffe et al. Third universal definition of myocardial infarction, Circulation 2012;126:2020-35. Go to original source... Go to PubMed...
  11. Apple FS, Wu AHB, Mair J, Ravkilde J, Panteghini M, Tate J, Pagani F, Christenson RH, Mockel M, Danne O, Jaffe AS. Future Biomarkers for Detection of Ischemia and Risk Stratification in Acute Coronary Syndrome. Clin Chem 2005;51:810-24. Go to original source... Go to PubMed...
  12. Rabitzsch G, Mair J, Lechleitner P, Noll F, Hofmann U, Krause EG, Dienstl F, Puschendorf B. Immunoenzymatic assay of human glycogen phosphorylase isoenzyme BB in diagnosis of ischemic myocardial injury. Clin Chem 1995;41:966-78. Go to original source...
  13. Horaček JM, Vasatova M, Tichy M, Pudil R, Jebavy L, Maly J. The use of cardiac biomarkers in detection of cardiotoxicity associated with conventional and high-dose chemotherapy for acute leukemia. Exp Oncol 2010;32,97-9.